
Melanotan-2
MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Melanotan-2 (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective melanocortin receptor agonist. Originally developed for skin pigmentation research, it has also been investigated for erectile dysfunction. NOT FDA approved and carries significant safety warnings from health agencies worldwide due to serious adverse effects including potential melanoma risk.
Clinical Benefits
Mechanism of Action
Melanotan-2 functions as a non-selective agonist of melanocortin receptors (MC1, MC3, MC4, and MC5). Primary mechanism involves binding to MC1 receptors on melanocytes, activating adenylyl cyclase and increasing cyclic adenosine monophosphate (cAMP) levels. This leads to activation of protein kinase A (PKA) and phosphorylation of cAMP response element-binding protein (CREB), ultimately stimulating transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase, key enzymes in melanin synthesis. MC4 receptor activation in the central nervous system affects sexual behavior and appetite regulation through hypothalamic pathways, while MC3 receptor involvement may contribute to energy homeostasis effects.
Proven Results
Medical Disclaimer
CRITICAL WARNING: Melanotan-2 is NOT approved by the FDA or any major regulatory agency for human use. Health authorities worldwide have issued warnings against its use due to serious safety risks including potential melanoma, priapism, rhabdomyolysis, and systemic toxicity. This information is for educational and research purposes only. Any use requires medical supervision and carries significant legal and health risks. Consult healthcare providers for approved alternatives.